|
Oct 4
|
Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
|
|
Aug 7
|
Lyell Immunopharma: Q2 Earnings Snapshot
|
|
Aug 7
|
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
|
|
Jun 26
|
Lyell Immunopharma Shares Plunge On One Patient Death In CAR-T Cell Therapy Cancer Trial
|
|
Jun 26
|
Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
|
|
May 7
|
Lyell Immunopharma to Participate in BofA Securities Health Care Conference
|
|
May 7
|
Lyell Immunopharma First Quarter 2024 Earnings: US$0.24 loss per share (vs US$0.27 loss in 1Q 2023)
|
|
May 6
|
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
|
|
Mar 17
|
Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) market cap decline of US$89m may not have as much of an impact on institutional owners after a year of 1.4% returns
|
|
Mar 7
|
Lyell Immunopharma (LYEL) Is Up 28.45% in One Week: What You Should Know
|
|
Mar 5
|
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
|
|
Nov 9
|
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
|
|
Nov 7
|
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
|
|
Sep 27
|
Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
|